Dearborn Partners LLC Makes New $12.64 Million Investment in Zoetis Inc. $ZTS

Dearborn Partners LLC purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the 2nd quarter, HoldingsChannel reports. The firm purchased 106,920 shares of the company’s stock, valued at approximately $12,639,000.

Other large investors have also recently modified their holdings of the company. Louisiana State Employees Retirement System bought a new stake in shares of Zoetis in the first quarter worth about $2,542,000. Wealthfront Advisers LLC raised its position in Zoetis by 80.2% during the 2nd quarter. Wealthfront Advisers LLC now owns 76,113 shares of the company’s stock valued at $5,469,000 after purchasing an additional 33,873 shares during the last quarter. Deutsche Bank AG raised its position in Zoetis by 19.1% during the 4th quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock valued at $699,331,000 after purchasing an additional 891,921 shares during the last quarter. Pincus Capital Management LP purchased a new stake in Zoetis in the 4th quarter worth approximately $2,109,000. Finally, Diamond Hill Capital Management LLC Investment Advisor lifted its holdings in Zoetis by 21.5% in the 2nd quarter. Diamond Hill Capital Management LLC Investment Advisor now owns 3,557,436 shares of the company’s stock worth $255,637,000 after buying an additional 629,974 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

ZTS has been the topic of several analyst reports. BNP Paribas Exane dropped their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 11th. HSBC decreased their price objective on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a report on Monday, July 6th. Zacks Research downgraded Zoetis from a “hold” rating to a “strong sell” rating in a research note on Monday, August 10th. Citigroup decreased their price target on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. Finally, JPMorgan Chase & Co. lowered their price target on Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Zoetis currently has an average rating of “Hold” and a consensus price target of $109.23.

Zoetis Trading Down 0.8%

Shares of NYSE:ZTS opened at $77.13 on Tuesday. The stock’s 50-day simple moving average is $75.70 and its two-hundred day simple moving average is $96.81. The stock has a market capitalization of $31.87 billion, a price-to-earnings ratio of 12.71, a PEG ratio of 1.82 and a beta of 0.73. Zoetis Inc. has a 52-week low of $71.00 and a 52-week high of $157.21. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. The firm had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business’s revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Analysts expect that Zoetis Inc. will post 6.2 EPS for the current year.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.